share_log

Brookline Capital Initiates Coverage On Immunic With Buy Rating, Announces Price Target of $10

Brookline Capital Initiates Coverage On Immunic With Buy Rating, Announces Price Target of $10

布魯克林資本以買入評級啓動對Immunic的報道,宣佈目標股價爲10美元
Moomoo 24/7 ·  04/05 04:59

Brookline Capital analyst Tyler Bussian initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and announces Price Target of $10.

布魯克林資本分析師泰勒·布西安以買入評級啓動了對Immunic(納斯達克股票代碼:IMUX)的報道,並宣佈目標股價爲10美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論